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A B S T R A C T   
Importance: Bradyarrhythmia during COVID19 illness carries prognostic significance. Electrophysiological side 
effects of COVID19 vaccine remain largely unknown. It is imperative to report nature of cardiovascular side 
effects of the vaccine. 
Case presentation: An 80 years-old-man presented with complains of dizziness, trepidation and shortness of breath 
following his first shot of COVID-19 BBIBP-CorV (Sino-pharm). ECG on arrival showed 2:1 atrioventricular block 
with an underlying old left bundle branch block. The AV block changed into Mobitz type-I over the course of next 
2 days and into a sinus 1:1 conduction on fourth day of presentation. However, our patient underwent permanent 
pacemaker implantation due to the underlying conduction tissue disease and intermittent 2:1 AV block during 
the hospital stay. 
Clinical discussion: It is likely that patients with an already diseased conduction system are at an increased risk of 
worsening of AV block following inoculation of the vaccine. Vaccine associated AV blocks are likely to be 
reversible. Presence of prior coronary artery disease and electrical abnormalities are important considerations. 
Conclusion: COVID-19 vaccine may have added side effects in subjects with known heart disease. Humoral 
response towards the vaccine might interfere with the conduction system of the heart and more so in patients 
with diseased and scarred myocardium.   
1. Introduction 
The association of COVID-19 illness and bradyarrhythmia has been 
well reported during the pandemic [1–4]. Bradyarrhythmia during 
COVID-19 illness carries prognostic significance [5]. Cytokine/in-
flammatory storm, hypoxia, electrolyte imbalances, and myocardial 
injury is thought to contribute to the arrhythmogenesis during the 
illness [6]. 
The AstraZeneca vaccine analysis report published on April 01, 
2021, has reported few heart blocks, the details of which are not known 
[7]. The literature is silent over any possibility of AV block following 
COVID-19 BBIBP-CorV. In this report, we present a case of a transient 
worsening of conduction block following COVID-19 vaccination 
(BBIBP-CorV) in an 80-year-old-man who had prior coronary artery 
disease. 
The case report has been reported in line with the SCARE 2020 
criteria [8]. 
2. Case presentation 
An 80-year-old-man presented with complains of multiple episodes 
of dizziness and trepidation for 3 days and shortness of breath for one 
day. On arrival, patient had blood pressure of 160/100 mmHg, heart 
rate of 46 beats per minute (BPM), respiratory rate of 19 breaths per 
minute and oxygen saturation of 94% on room air. Physical examination 
was suggestive of a regular pulse and bi-basal chest crackles. There was 
no postural drop or neurological deficit. There were no signs of pe-
ripheral hypoperfusion such as cold peripheries, reduced urine output, 
or altered mentation. Precordial examination revealed no added sound 
or murmur. All peripheral pulses were palpable and equal. The patient 
was known hypertensive and had history of coronary artery bypass 
grafting (CABG) 18-years ago. Drug history included: Aspirin, Ivabra-
dine and amlodipine (unchanged for last many years; no regular follow- 
up with cardiologist). Patient had no known addictions and psychosocial 
history was insignificant. Patient has had no previous similar episodes. 
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Five days before the presentation, patient had received his first shot of 
BBIBP-CorV (Sino-pharm). 
Electrocardiogram (ECG) on arrival showed 2:1 atrioventricular 
(AV) block with an atrial rate of approximately 75 BPM and a ventricular 
rate of approximately 38 BPM. The PR interval of conducted P wave was 
280 msec and there was an underlying old left bundle branch block 
(LBBB) (Fig. 1). Laboratory investigation revealed a hemoglobin of 12 g/ 
dl, white cell count of 8.5 *10^9, Troponin-I of 0.03 ng/ml (cut off 0.04), 
creatinine of 0.9 mg/dl (cutoff 1.3), Sodium of 121 mmol/L (cutoff 136), 
Potassium of 4.1 mmol/L, bicarbonate of 21.4 mmol/L (cutoff 21), C- 
reactive protein of 20 mg/L, magnesium of 1.7 mg/dL (cut off 1.6), and 
calcium of 8.5 mg/dL (cutoff 8.6). Nasopharyngeal COVID-19 PCR was 
negative. Patient had a thyroid stimulating hormone (TSH) of 3.9 uIU/ 
ml. 
Echocardiogram was done which showed an ejection fraction (EF) of 
60% along with mild mitral regurgitation, moderate tricuspid regurgi-
tation, and moderate pulmonary arterial hypertension. Owing to the 
hemodynamic stability, and absence of signs of hypoperfusion, tempo-
rary pacemaker (TPM) was not inserted. Patient was admitted to the 
Coronary Care Unit (CCU) of the hospital. Ivabradine was discontinued 
and patient was observed for any change in rhythm. On day three of CCU 
admission, patient’s rhythm changed to Mobitz type-I AV block with a 
serial PR interval of 280 and 360 msec followed by a dropped beat 
(Fig. 2). Older ECGs of same patient were retrieved dating back to 2010 
and 2018. The ECG from 2010 showed a normal sinus rhythm with an 
LBBB and a PR interval of 180 msec (Fig. 3). The ECG from 2018 showed 
similar findings except for a PR interval of 200 msec (an absolute in-
crease in PR interval of 20 msec over 8 years) (Fig. 4). 
Patient was further observed and mobilized cautiously with no 
resultant worsening of AV block. On day four of hospitalization, pa-
tient’s rhythm changed to a normal sinus rhythm with 1:1 P and QRS 
conduction (Fig. 5). The PR interval remained 280 msec with an un-
derlying LBBB. Occasionally, patient went into intermittent short-lasting 
2:1 AV block. 
Possible differentials for an acute AV block were electrolyte imbal-
ance, ivabradine and conduction system disease progression. Disease 
progression was indeed present due to an increase in first degree AV 
block. However, the reversibility in P to QRS conduction abnormality 
pointed towards an acute insult which resulted in a new onset 
symptomatic bradycardia. Persistence of AV block even after correction 
of sodium suggests that hyponatremia was unlikely to be the culprit. Our 
patient was on Ivabradine for last many years, however, again the 
acuteness of onset goes against the ivabradine being culprit. Hence, it 
was concluded that COVID-19 vaccination transiently worsened the AV 
block in our patient. Myocarditis was ruled out because of negative 
cardiac biomarkers and normal EF. 
Because of the age, symptomatic documented bradycardia, an un-
derlying AV node (first degree AV block) and infra-HIS disease (LBBB), 
an expected life expectancy of more than one year, and because of the 
recurrence of intermittent 2:1 block during the hospital course, a deci-
sion to place a dual-chamber permanent pacemaker (PPM) was made. 
Patient underwent successful device placement (Fig. 6). The procedure 
was performed by electrophysiologist-on-call in electrophysiology lab of 
the hospital. Post-procedure, patient was monitored for symptoms. 
There was no recurrence of symptoms and patient was well-mobilized. 
He was discharged home the next day, and he followed up in cardiol-
ogy clinic with improvement in shortness of breath and no recurrence of 
dizziness or syncope. 
3. Discussion 
In a phase I/II BBIBP-CorV (Sino-pharm) vaccine trial conducted in 
Henan province of China, no atrioventricular block was reported [9]. 
However, 29% of the total recipients experienced at least one side effect 
in first 7 days of inoculation. In another phase I trial, patients with 
cardiovascular diseases were largely excluded and no arrhythmia was 
reported [10]. Likewise, another phase I/II trial reported no adverse 
events pertinent to cardiac arrhythmia [11]. 
The concept of humoral immune response and AV block is not novel. 
The association of maternal anti-Ro and anti-La antibodies and 
congenital complete heart block (CHB) is well known [12]. Like the 
pattern of maternal antibody immune complex deposition in congenital 
CHB leading to inflammation and fibrosis in fetal conduction tissue, it is 
very likely for the inactivated BBIBP-CorV vaccine to have similar 
pathophysiological basis for causing AV block. In a prospective study of 
24 anti-Ro positive pregnant women, 33% of fetuses showed evidence of 
first-degree AV block, with one fetus showing progression to CHB and 
another showing shift in degree of AV block from second to first degree. 
Fig. 1. Electrocardiogram on arrival showing 2:1 atrioventricular (AV) block with an atrial rate of approximately 75 BPM and a ventricular rate of approximately 38 
BPM. The PR interval was 280 msec. The ECG showed old LBBB. 
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Yet another 6 fetuses, showed resolution of AV block at or soon after 
birth. Considering this study, it can be interpreted that 
antibody-associated AV blocks are usually transient (as in our case). 
Vaccine-associated AV block has been reported in literature after 
inoculation of small-pox vaccine in 2003 [13]. In this case, a 56-year--
old-man was reported to have first degree AV block and negative car-
diac biomarker on day 23 of the vaccination. Likewise, an intermittent 
incomplete right bundle branch block (RBBB) was also reported after 
small-pox vaccination in 2009 [14]. 
The transient nature of AV block in our patient following COVID-19 
vaccination can be linked to the pathophysiology of transient and 
various degrees of heart blocks associated with Lyme carditis. This was 
evident in an experiment on non-human primates injected with Borrelia 
burgdorferi strains, whereby an increase in IgG and IgM levels in re-
cipients was observed. There was an accompanying increased deposition 
of complement-membrane attack complex [15]. The reversible nature of 
Lyme carditis-AV block is due to the parallelly reduced degree of 
inflammation over time-course in experimental mouse-models [16]. 
This stretches our thought process to the possible role of 
endomyocardial biopsy (EMB) in COVID-19-vaccine associated AV 
block. EMB is found to demonstrate myocardial lesions other than 
myocarditis in patients with primary AV block of unknown etiology 
[17]. EMB, as of now, is not recommended in patients with COVID-19 
suspected of having myocarditis [18]. However, like its indication in 
unexplained early AV blocks [19], EMB can be considered in patients 
with transient nature of AV block following COVID-19 vaccination. 
Prognostic significance of EMB in COVID-19 associated AV blocks [20] 
needs further validation. 
Our patient presented with the onset of symptoms 3 days following 
COVID-19 vaccination. The time scale (within first 7 days of inocula-
tion) between vaccination and worsening of AV block points towards 
possible association. Additionally, the reversibility of AV block in next 
few days also points towards an acute insult rather than a chronic 
irreversible worsening of conduction system tissue. It is likely that pa-
tients with an already diseased conduction system are at an increased 
risk of worsening of AV block following inoculation of the vaccine. 
The role of steroids in COVID-19-vaccine associated AV block needs 
further research [21]. It can be extrapolated from the study that looked 
Fig. 2. Electrocardiogram on day three showing Mobitz type-I AV block with a serial PR interval of 280 and 360 msec followed by a dropped beat.  
Fig. 3. Electrocardiograms of patient from 2010 showing an old LBBB with a PR interval of 180msec.  
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Fig. 4. Electrocardiograms of the same patient from 2018 showing an old LBBB with a PR interval of 200 msec.  
Fig. 5. Electrocardiogram on day fourth of presentation showing a normal sinus rhythm with 1:1 P to QRS conduction and a persistent first-degree AV block (PR 
interval 280 msec). 
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at the benefits of antenatal steroids in treatment of congenital CHB 
whereby, steroids conferred no mortality benefit but significantly 
downgraded the degree of AV block [22]. Based on our experience in 
this case, we hereby propose an algorithm to identify healthy COVID-19 
vaccine recipients who are at an increased risk of developing worsening 
AV block. The individualized decision for permanent device placement 
is re-enforced (Fig. 7). 
Given the extensive use of vaccination in general population 
including patients with ischemic heart diseases, reporting such cases is 
imperative. Physicians should be cognizant of the possibility of wors-
ening of AV block following vaccination. Watchful waiting strategy can 
be applied in patients with low-risk baseline ECG whereas an early 
pacemaker implantation can be considered in patients with high-risk 
baseline ECG and having an indication for PPM. 
4. Conclusion  
• Patients with underlying existing conduction tissue disease might be 
at an increased risk of worsening of AV block following inoculation 
of BBIBP-CorV vaccine.  
• Reversibility or intermittency is commonly seen with vaccine- or 
antibody-associated AV blocks.  
• The decision to implant PPM in vaccine-associated AV block should 
be individualized, as discussed below. 
• In patients with absence of an underlying coronary artery or con-
duction system disease, COVID-19 vaccine associated AV block 
might be transient and watchful strategy can be employed.  
• In presence of an underlying coronary artery or conduction system 
disease, one must be considerate of the symptom-bradycardia cor-
relation, the degree of underlying block, patient’s life expectancy 
and the overall benefit of device implantation. 
Fig. 6. Electrocardiogram showing atrioventricular sequential pacing after permanent pacemaker insertion.  
Fig. 7. The proposed strategy to identify healthy COVID-19 vaccine recipients who are at increased risk of developing worsening atrioventricular block.  
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• EMB might emerge as a prognostic tool to guide decision for PPM 
implantation in patients with transient nature of AV blocks following 
a humoral response. 
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